Corbus Pharmaceuticals

Corbus Pharmaceuticals to Present at the Annual B. Riley FBR Healthcare Conference

Ziad2022-11-25T14:04:54-05:00Corbus Pharmaceuticals Holdings, Inc., a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present at the Annual B. Riley FBR Healthcare Conference on Tuesday, September 4, 2018 at 9:25 a.m. EDT in New York, NY. Read more >>

Corbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis

Ziad2022-11-25T14:04:54-05:00Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that the Company will proceed with a Phase 3 trial evaluating the efficacy and safety of lenabasum for the treatment of dermatomyositis (“DM”). Dermatomyositis is a rare and serious multisystem inflammatory autoimmune disease affecting muscle and skin. The U.S. Food and Drug Administration (“FDA”) provided guidance on the overall study design of this trial at a recent end-of-Phase 2 meeting....

Corbus Pharmaceuticals Receives FDA Orphan Drug Designation for Lenabasum for the Treatment of Dermatomyositis

Ziad2022-11-25T14:04:54-05:00Corbus Pharmaceuticals Holdings, Inc., a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases, announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to lenabasum, its novel, synthetic oral endocannabinoid-mimetic drug, for the treatment of dermatomyositis. Read more >>

Lenabasum Continues to Show Promise for Treatment of Systemic Sclerosis in Extension Study

Ziad2022-11-25T14:05:04-05:00Treatment with Corbus Pharmaceuticals’ investigative therapy lenabasum (formerly known as anabasum) significantly improves the symptoms of diffuse cutaneous systemic sclerosis in a Phase 2 open-label extension study. Read more >>

Corbus Pharmaceuticals Announces Resolution of Inflammation, Infection and Tissue Regeneration Conference

Ziad2022-11-25T14:05:04-05:00Corbus Pharmaceuticals Holdings, Inc., a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory diseases, announced that it will be presenting at the Resolution of Inflammation, Infection and Tissue Regeneration Conference in partnership with the New York Academy of Sciences (NYAS), taking place on Tuesday, June 26, 2018 in New York City. Read more >>

Corbus Pharmaceuticals Presents 1-Year Systemic Sclerosis and 6-Month Dermatomyositis Data from Open-Label Extension of Phase 2 Lenabasum Studies at EULAR 2018

Ziad2022-11-25T14:05:04-05:00Corbus Pharmaceuticals Holdings, Inc., a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases, announced today that data from open-label extensions (OLEs) of its systemic sclerosis (SSc) and dermatomyositis (DM) Phase 2 studies are being presented at the Annual European Congress of Rheumatology (EULAR 2018). Read more >>

Corbus Pharmaceuticals Adds Two Key Executives to Lead its Regulatory and CMC Operations

Ziad2022-11-25T14:05:05-05:00Corbus Pharmaceuticals Holdings, Inc., a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases, announced today the appointment of Robert Discordia, Ph.D., as Vice President, Pharmaceutical Development & Manufacturing, and Ross Lobell as Vice President, Regulatory Affairs. Dr. Discordia will oversee all aspects of Corbus’ chemistry, manufacturing and controls (CMC) for lenabasum and future drug candidates. Mr. Lobell will lead Corbus’ Regulatory Affairs and Quality...

Corbus Pharmaceuticals Announces Acceptance of Three Abstracts for Presentation at EULAR 2018 Annual Meeting

Ziad2022-11-25T14:05:05-05:00Corbus Pharmaceuticals Holdings, Inc., a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases, announced today that its abstracts have been accepted for presentation at the European League Against Rheumatism ("EULAR") 2018 Annual Meeting being held June 13-16, 2018 in Amsterdam, Netherlands. Read more >>

Corbus Pharmaceuticals to Present at the 7th Annual LEERINK Partners Global Healthcare Conference

Ziad2022-11-25T14:05:16-05:00Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present in a fireside chat at the 7th Annual LEERINK Partners Global Healthcare Conference on Thursday, February 15th at 2:30 p.m. EST in New York, NY. Read more >>

Corbus Pharmaceuticals Announces Agreement with FDA on Phase 2b Cystic Fibrosis Study Design with Pulmonary Exacerbations as Sole Primary Endpoint

Ziad2022-11-25T14:05:16-05:00Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration ("FDA") regarding the design of its next study of lenabasum (formerly known as anabasum), a novel, oral, pro-resolving drug, in the treatment of cystic fibrosis ("CF"). Read more >>